Cart
sales@molnova.com
KRas-IN-1
CAS No. 84783-01-7
KRas-IN-1( MDK-3017 | MDK3017 | MDK 3017 | K-Ras-IN-2 | K-Ras Inhibitor-2 )
Catalog No. M16153 CAS No. 84783-01-7
A chemical fragment hit that binds to K-Ras (G12D) with affinities of 1.3-2 mM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 46 | In Stock |
|
| 5MG | 43 | In Stock |
|
| 10MG | 68 | In Stock |
|
| 25MG | 126 | In Stock |
|
| 50MG | 194 | In Stock |
|
| 100MG | 291 | In Stock |
|
| 200MG | 403 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKRas-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionA chemical fragment hit that binds to K-Ras (G12D) with affinities of 1.3-2 mM.
-
DescriptionA chemical fragment hit that binds to K-Ras (G12D) with affinities of 1.3-2 mM; binds to K-Ras in a hydrophobic pocket that is occupied by Tyr-71 in the apo-Ras crystal structure.
-
In Vitro——
-
In Vivo——
-
SynonymsMDK-3017 | MDK3017 | MDK 3017 | K-Ras-IN-2 | K-Ras Inhibitor-2
-
PathwayMAPK/ERK Signaling
-
TargetRas
-
RecptorRas
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number84783-01-7
-
Formula Weight207.292
-
Molecular FormulaC11H13NOS
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 28 mg/mL
-
SMILESS=C(C1=CC=CC=C1O)N2CCCC2
-
Chemical NameMethanethione, (2-hydroxyphenyl)-1-pyrrolidinyl-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sun Q, et al. Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6140-3.
molnova catalog
related products
-
PDEδ-IN-99
PDEδ-IN-99 is a novel potent K-Ras-PDEδ inhibitor that binds to the farnesyl binding pocket of PDEδ with Kd of 8±4 nM.
-
BI-2852
BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) with nanomolar affinity.
-
MRTX1133
MRTX1133 is a potent, selective, noncovalent KRASG12D inhibitor. It has picomolar binding affinity, single-digit nanomolar activity in cellular assays. In addition, it has significant in vivo efficacy in tumor models harboring KRASG12D mutations.
